Do irbesartan and amlodipine reduce cardiovascular events in diabetic patients?
Millard, P.S.
Journal of Family Practice 52(8): 593-594
2003
ISSN/ISBN: 0094-3509 PMID: 12899808 Document Number: 561862
When added to antihypertensive treatment in patients with diabetes and nephropathy, neither the angiotensin receptor blocker (ARB) irbesartan nor the calcium channel blocker amlodipine reduced the overall occurrence of cardiovascular events. However, irbesartan decreased the rate of heart failure and amlodipine reduced the rate of acute myocardial infarction.
Document emailed within 1 workday
Related Documents
Ebell, M.H. 2017: In Patients with Vascular Disease, Treating Sleep Apnea Does Not Reduce the Risk of Cardiovascular Events American Family Physician 95(2): 123-123Nilsson, P.M.; Håkansson, J. 2005: Amlodipine better than atenolol in hypertension. More efficient prevention of the mortality and cardiovascular events according to the ASCOT trial Lakartidningen 102(41): 2922-2923
Rohra, D.Kumar.; Maheshwary, A.Raysee.; Gauba, S.Shamlal. 2007: Prevalence of cardiovascular events in diabetic patients taking sulphonylureas: need for assessment Jpma. Journal of the Pakistan Medical Association 57(3): 163
Chen, Y.; Wang, J.; An, Y.; Gong, Q.; He, Y.; Zhang, B.; Li, H.; Shuai, Y.; Tang, X.; Jiang, Y.; Hong, J.; Yang, W.; Hu, Y.; Li, G. 2015: Effect of lifestyle interventions on reduction of cardiovascular disease events and its mortality in pre-diabetic patients:long-term follow-up of Da Qing Diabetes Prevention Study Zhonghua Nei Ke Za Zhi 54(1): 13-17
Spinar, J.; Vítovec, J. 2012: AIi antagonists (candesartan and irbesartan) in the treatment of cardiovascular diseases Vnitrni Lekarstvi 58(10): 755-760
Fellah, H.; Feki, M.; Feki, H.; Souissi, M.; Kaabachi, N.; Abdallah, T.B.; Massy, Z.A.; Maiz, H.B.; Lacour, B.; Mebazaa, A. 2004: Classical and "Non-classical" Cardiovascular Risk Factors in Tunisian Patients with End Stage Renal Disease: Prevalence and Association with Cardiovascular Events Clinical Laboratory 50(7-8): 447-453
2005: To lessen the cardiovascular risk of the diabetic patient. Atorvastatin of use for diabetic patients without coronary disease, too MMWFortschrittederMedizin 147(33-34): 51
Oganov, R.G.; Gratsianskiĭ, N.A.; Mazur, N.A.; Lazebnik, L.B.; Belousov, I.B.; Sidorenko, B.A.; Ol'binskaia, L.I.; Vertkin, A.L.; Shevchenko, O.P.; Karpov, I.A. 1992: Circadian rhythm in the clinical course of cardiovascular diseases. Clinical experience using Norvasc (amlodipine) in the treatment of patients with ischemic heart disease and arterial hypertension Kardiologiia 32(5): 99-112
2014: Ivabradine and patients with coronary artery disease: more cardiovascular events Prescrire international 23(155): 295
Guo, Y.F. 2019: Effects of aspirin on primary prevention of cardiovascular events in patients with hypertension Zhonghua Nei Ke Za Zhi 58(4): 249-251
Yamaguchi, S.; Gohda, T.; Gotoh, H.; Omote, K.; Furukawa, M.; Ishikawa, Y.; Tomino, Y. 2013: Factors associated with cardiovascular death and events in patients with end stage renal disease Nihon Jinzo Gakkai Shi 55(2): 159-166
Nossent, H. 2000: Risk of cardiovascular events and effect on mortality in patients with rheumatoid arthritis Journal of Rheumatology 27(9): 2282-2283
Hartley, H. 1996: The reduction of cardiovascular events after a myocardial infarct in patients with normal cholesterol levels Revista Clinica Espanola 196(4 Monografico): 43-46
Jungers, P.; Nguyen Khoa, T.; Massy, Z.A.; Man, N.K. 1998: Incidence of atherosclerotic cardiovascular events in patients with chronic uremia: epidemiologic studies in Ile-de-France Nephrologie 19(8): 489-494
Klomp, C.M.C.; ten Cate, H.; Stehouwer, C.D.A.; Schaper, N.C. 2009: Acetylsalicylic acid in patients with diabetes mellitus: can be used for secondary but not primary prevention of cardiovascular events Nederlands Tijdschrift Voor Geneeskunde 153: A109
Zhao, Y.; Wang, W.Y.; Tian, J.; Zhang, X.; Yang, M.; Chen, J.; Mu, M.; Tang, Y.D. 2019: Impact of low T3 syndrome on adverse cardiovascular events in adult patients with acute viral myocarditis Zhonghua Xin Xue Guan Bing Za Zhi 47(6): 447-451
Gollapudi, A.K. 2008: Do lipid-lowering agents provide a greater reduction in cardiovascular events among patients with diabetes? Annals of Internal Medicine 149(11): 841; Author Reply 841-2
Suppadungsuk, S.; Yamwong, S.; Sungkanuparph, S. 2013: Risk of cardiovascular events predicted by the Rama-EGAT score among HIV-infected patients in Thailand Southeast Asian Journal of Tropical Medicine and Public Health 44(5): 818-824
Bissonnette, R.; Kerdel, F.; Naldi, L.; Papp, K.; Galindo, C.; Langholff, W.; Tang, K.L.; Szapary, P.; Fakharzadeh, S.; Srivastava, B.; Goyal, K.; Gottlieb, A.B. 2017: Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis Journal of Drugs in Dermatology: Jdd 16(10): 1002-1013
Komarov, A.N.; Lisichenko, D.A.; I, S.Cher.; Silina, E.V.; Biktasheva, R.M.; Stakhovskaia, L.V.; Ivanova, G.E. 2013: Investigation of risk factors of cardiovascular events by the interregional assistance fund of relatives of stroke patients Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 113(12 Pt 2): 3-6